48,710 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by HealthInvest Partners AB

HealthInvest Partners AB bought a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 48,710 shares of the biopharmaceutical company’s stock, valued at approximately $691,000.

Other institutional investors have also added to or reduced their stakes in the company. Metropolitan Life Insurance Co NY increased its holdings in Amicus Therapeutics by 4.9% in the 4th quarter. Metropolitan Life Insurance Co NY now owns 16,962 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 797 shares in the last quarter. Pathstone Family Office LLC raised its position in shares of Amicus Therapeutics by 0.8% during the 4th quarter. Pathstone Family Office LLC now owns 102,720 shares of the biopharmaceutical company’s stock valued at $1,254,000 after purchasing an additional 809 shares during the period. MetLife Investment Management LLC lifted its stake in shares of Amicus Therapeutics by 0.7% during the 4th quarter. MetLife Investment Management LLC now owns 146,423 shares of the biopharmaceutical company’s stock valued at $1,788,000 after buying an additional 947 shares in the last quarter. Stifel Financial Corp boosted its holdings in Amicus Therapeutics by 1.0% in the 3rd quarter. Stifel Financial Corp now owns 106,130 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 1,098 shares during the period. Finally, Envestnet Asset Management Inc. raised its holdings in Amicus Therapeutics by 0.8% during the first quarter. Envestnet Asset Management Inc. now owns 145,259 shares of the biopharmaceutical company’s stock valued at $1,611,000 after acquiring an additional 1,182 shares during the period.

Analyst Ratings Changes

Several research firms recently issued reports on FOLD. Morgan Stanley upgraded Amicus Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $15.00 to $20.00 in a research report on Tuesday, December 19th. Cantor Fitzgerald restated an “overweight” rating and set a $22.00 target price on shares of Amicus Therapeutics in a research report on Thursday, February 29th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Monday, March 18th.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock traded down $0.10 during mid-day trading on Tuesday, reaching $10.56. 2,800,442 shares of the company’s stock traded hands, compared to its average volume of 3,021,672. Amicus Therapeutics, Inc. has a 12-month low of $9.70 and a 12-month high of $14.57. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.88 and a quick ratio of 2.52. The stock has a 50 day moving average of $12.39 and a two-hundred day moving average of $12.04.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Amicus Therapeutics had a negative return on equity of 119.46% and a negative net margin of 37.96%. The business had revenue of $115.08 million during the quarter, compared to the consensus estimate of $115.11 million. As a group, equities research analysts predict that Amicus Therapeutics, Inc. will post 0.02 EPS for the current year.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 4,167 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $14.00, for a total value of $58,338.00. Following the completion of the sale, the chief executive officer now directly owns 871,219 shares of the company’s stock, valued at approximately $12,197,066. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Bradley L. Campbell sold 4,167 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $58,338.00. Following the transaction, the chief executive officer now directly owns 871,219 shares in the company, valued at approximately $12,197,066. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Margaret G. Mcglynn sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $13.40, for a total value of $100,500.00. Following the transaction, the director now directly owns 59,289 shares in the company, valued at approximately $794,472.60. The disclosure for this sale can be found here. Insiders have sold a total of 103,435 shares of company stock worth $1,346,447 over the last ninety days. Company insiders own 2.10% of the company’s stock.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.